An experimental Parkinson’s drug missed its primary goal in a mid-stage trial, Roche said, in what is the second setback this week for candidate treatments for the neurodegenerative condition.
Related Posts
Kingfisher Narrows Profit Forecast After Sales Miss
Kingfisher said recent political and macroeconomic events are adding further uncertainty to its outlook after it posted worse-than-expected quarterly sales and narrowed down its profit […]
Basic Materials Roundup: Market Talk
Find insight on Endeavour Mining, South32 and more in the latest Market Talks covering Basic Materials.
AstraZeneca Probe in China Adds to Concerns for Foreign Businesses
An investigation involving the drugmaker’s China president is the latest industry crackdown to trigger uncertainty about Beijing’s intentions.